Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Expert Opinion on Drug Safety|October 25, 2014
Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillationMikhail S Dzeshka, Gregory Yh LipExpert Opinion on Pharmacotherapy|November 13, 2015
Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillationMikhail S Dzeshka, Gregory Y H LipJournal of Atrial Fibrillation|December 14, 2016
Stroke And Bleeding Risk Assessment: Where Are We Now?Mikhail S Dzeshka, Gregory Y H LipCardiology Clinics|December 3, 2014
Antithrombotic and anticoagulant therapy for atrial fibrillationMikhail S Dzeshka, Gregory Y H LipHeart Failure Clinics|March 13, 2016
Antithrombotic and Anticoagulant Therapy for Atrial FibrillationMikhail S Dzeshka, Gregory Y H LipTrends in Cardiovascular Medicine|December 3, 2014
Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?Mikhail S Dzeshka, Gregory Y H LipExpert Review of Hematology|September 14, 2017
Direct oral anticoagulant reversal: how, when and issues facedMikhail S Dzeshka, Daniele Pastori, Gregory Y H LipCurrent Hypertension Reports|October 28, 2016
Effects of Aspirin on Endothelial Function and HypertensionMikhail S Dzeshka, Alena Shantsila, Gregory Y H LipPolskie Archiwum Medycyny Wewnetrznej|December 24, 2014
Patients with atrial fibrillation undergoing percutaneous coronary intervention: current concepts and concerns: part IIMikhail S Dzeshka, Richard A Brown, Gregory Y H LipClinical Cardiology|August 30, 2014
Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2 , CHA2 DS2 -VASc, R2 CHADS2 , HAS-BLED, ATRIA, and more)Mikhail S Dzeshka, Deirdre A Lane, Gregory Y H LipPageof 2